Congratulations to DBV Technologies on their Biologics License Application submission to the U.S. FDA for the VIASKIN® Peanut Patch for children ages 4–7. The skin patch delivers tiny amounts of peanut protein to gradually desensitize the immune system, with no oral dosing and no needles.
globenewswire.com
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in...